Frequently asked questions
Frequently asked questions
Embedded Files
Have questions about SUMOdulon, Inc., our science, or investment opportunities? We have answered the most common ones below. For anything else reach out to us directly.
What does SUMOdulon, Inc. do?
What does SUMOdulon, Inc. do?
SUMOdulon, Inc. develops small molecule inhibitors that target the SUMOylation system in cancer cells. Our compounds are designed to work alongside existing chemotherapy agents, restoring cancer cell sensitivity to treatment and improving patient outcomes.
What is SUMOylation?
What is SUMOylation?
SUMOylation is a cellular process in which Small Ubiquitin-like Modifier (SUMO) proteins are attached to and detached from target proteins. Cancer cells exploit this process to repair chemotherapy-induced DNA damage, effectively neutralizing treatment. SUMOdulon targets this pathway to restore chemotherapy effectiveness.
What stage is SUMOdulon at?
What stage is SUMOdulon at?
SUMOdulon, Inc. is currently at Technology Readiness Level 4 (TRL 4), meaning our lead compound SUM2IN has been validated in preclinical laboratory studies. We are advancing toward Phase 2 studies in preparation for Investigational New Drug (IND) application filing.
What cancers does SUMOdulon target?
What cancers does SUMOdulon target?
Our current pipeline prioritizes three cancer types where chemotherapy resistance is a significant clinical challenge: Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC), and Glioblastoma (GB).
How is SUMOdulon funded?
How is SUMOdulon funded?
SUMOdulon, Inc. received its initial seed funding of $20,000 through the 2024 Elevate Health Tech Challenge. We are currently seeking private investment and grant funding to advance our pipeline through the next phase of development.
How can I invest in or partner with SUMOdulon?
How can I invest in or partner with SUMOdulon?
We welcome conversations with investors, strategic partners, and collaborators. Please reach out to us directly at sumodulon@icloud.com and we will be happy to share more information.
Is SUMOdulon affiliated with a university?
Is SUMOdulon affiliated with a university?
SUMOdulon, Inc. was founded by Dr. German Rosas-Acosta, a tenured professor at The University of Texas at El Paso. Our research is rooted in work conducted at the SUMO Laboratory for Cellular and Molecular Biology at UTEP.
Where is SUMOdulon, Inc. based?
Where is SUMOdulon, Inc. based?
SUMOdulon, Inc. is based in El Paso, Texas.
Page updated
Google Sites
Report abuse